Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs reported strong FY25 results with standalone net sales rising ~38% to Rs. 18,158.73 lakhs (FY24: Rs. 13,159.90 lakhs) and net profit after tax jumping ~77% to Rs. 3,115.69 lakhs (FY24: Rs. 1,757.38 lakhs), lifting EPS to Rs. 19.37 from Rs. 11.03. On a consolidated basis, revenue grew ~28% to Rs. 19,831.85 lakhs and PAT nearly doubled to Rs. 2,494.01 lakhs. The statutory auditor C. Sharat & Associates issued an unqualified (unmodified) opinion on both standalone and consolidated results. The company significantly expanded its capital base, with capital work-in-progress rising sharply to Rs. 1,729.45 lakhs (from Rs. 596.50 lakhs) and new long-term borrowings of Rs. 2,777.04 lakhs, indicating major capex underway. Operating cash flow improved substantially to Rs. 1,523.28 lakhs (standalone) from a negative Rs. 258.16 lakhs in FY24.
Strong top-line and bottom-line growth with margin expansion is positive for shareholders. However, the sharp increase in borrowings and a large capital work-in-progress balance signal heavy ongoing investment, which could pressure short-term cash flows but supports future capacity. Overall, the results are constructive for the stock given robust earnings growth and a clean audit opinion.